One of Australia's leading clinician scientists and founder of national genomic cancer medicine centre, Omico, Professor David Thomas, received the ...

One of Australia’s leading clinician scientists and founder of national genomic cancer medicine centre, Omico, Professor David Thomas, received the state’s highest accolade for cancer research at the ...

Discover the results of a groundbreaking phase 3 trial presented at ACR 2024, showing upadacitinib's efficacy in managing ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

A chemotherapy-free regimen of neoadjuvant nivolumab (Opdivo) with or without ipilimumab (Yervoy) induced immune activation ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

We congratulate the eleven researchers at the Department of Cell and Molecular Biology who have been awarded grants from the ...

Upadacitinib 15 mg plus a 26-week GC taper outperformed placebo in combination with a 52-week GC taper for the treatment of ...

British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of ...

They gave me some literature to read about the hallmarks of cancer and some stuff on small cell lung cancer, and we still ...